Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals, Inc.

Tisento Therapeutics Inc.

Karthik Iyer

Paul A Renhowe

Glen Robert Rennie

Rajesh R Iyengar

Joon Jung

Takashi Nakai

Ara Mermerian

Thomas Wai-Ho Lee

G-Yoon Jamie Im

Timothy Claude Barden

James Edward Sheppeck

Nicholas Robert Perl

Mark G Currie

Xiang Y Yu

Joel D Moore

Lei Jia

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

James Jia

Kim Tang

Peter Germano

Paul Allen Renhowe

Paul Allan Renhowe

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

SGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

Growing community of inventors

Cambridge, MA, United States of America

Karthik Iyer